
Over 240 million people worldwide live with chronic hepatitis B

The new three-year agreement builds on an existing two-year relationship

The antibiotics are needed to combat key drug-resistant bacteria causing severe bloodstream and urinary tract infections, pneumonia and meningitis

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

RSV affects approximately 64 million people around the world each year

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

The treatment demonstrated non-inferiority to current standard of care

Approval supported by positive results from phase 3 trial

The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

The partnership will provide financial support and strengthen early detection and intervention efforts

The new antibiotic class targets two of the WHO’s ‘priority pathogens’

The deal includes a PDE3/4 inhibitor in clinical development for COPD